Literature DB >> 2592535

Systemic and local antibody responses in elderly subjects given live or inactivated influenza A virus vaccines.

D C Powers1, S D Sears, B R Murphy, B Thumar, M L Clements.   

Abstract

Intranasal live attenuated cold-adapted (ca) influenza A/Kawasaki/9/86 (H1N1) reassortant virus and parenteral inactivated influenza A/Taiwan/1/86 (H1N1) virus were given alone or in combination to 80 ambulatory elderly subjects. An enzyme-linked immunosorbent assay was used to measure hemagglutinin-specific (HA) antibodies in serum and nasal wash specimens collected before vaccination and 1 and 3 months later. Serum immunoglobulin G (IgG) and nasal wash IgA HA responses were elicited in 56 and 20%, respectively, of 25 inactivated-virus vaccinees and in 67 and 48%, respectively, of 27 recipients of both vaccines but in only 36 and 25%, respectively, of 28 vaccinees given live virus alone. Inactivated virus, administered alone or with live virus vaccine, induced higher titers of serum antibody than did the live virus alone. In contrast, nasal IgA HA antibody was elicited more often and in greater quantity by the vaccine combination than by either vaccine alone. Despite these differences, the peak titers of local antibody mounted by each group of vaccinees were similar. By 3 months postvaccination, serum IgG and nasal IgA HA antibody titers remained elevated above prevaccination levels in 50 and 17%, respectively, of the inactivated-virus vaccinees and in 46 and 23%, respectively, of recipients of both vaccines but in only 19 and 7%, respectively, of the live-virus and systemic antibodies, if vaccinees. The finding that live ca influenza A virus induced short-lived local and systemic antibodies, if confirmed, suggests that live virus vaccination may not be a suitable alternative or adjunct to inactivated virus vaccination for the elderly.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2592535      PMCID: PMC267105          DOI: 10.1128/jcm.27.12.2666-2671.1989

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  34 in total

1.  Influenza subunit vaccine: antibody responses to one and two doses of vaccine and length of response, with particular reference to the elderly.

Authors:  J S MacKenzie
Journal:  Br Med J       Date:  1977-01-22

2.  Responses of elderly subjects to monovalent A/USSR/77 (H1N1) and Trivalent A/USSR/77 (H1N1)-A/TEXAS/77 (H3N2)-B/Hong Kong/72 vaccines.

Authors:  M W Brandriss; R F Betts; U Mathur; R G Douglas
Journal:  Am Rev Respir Dis       Date:  1981-12

3.  Impact of epidemic type A influenza in a defined adult population.

Authors:  W H Barker; J P Mullooly
Journal:  Am J Epidemiol       Date:  1980-12       Impact factor: 4.897

4.  Antigenicity of licensed whole virion and subvirion influenza vaccines in "high risk" persons.

Authors:  J A Kasel; R B Couch; H R Six; V Knight
Journal:  Proc Soc Exp Biol Med       Date:  1976-04

5.  Hemagglutinin-specific enzyme-linked immunosorbent assay for antibodies to influenza A and B viruses.

Authors:  B R Murphy; M A Phelan; D L Nelson; R Yarchoan; E L Tierney; D W Alling; R M Chanock
Journal:  J Clin Microbiol       Date:  1981-03       Impact factor: 5.948

6.  Cold-adapted variants of influenza A virus: evaluation in adult seronegative volunteers of A/Scotland/840/74 and A/Victoria/3/75 cold-adapted recombinants derived from the cold-adapted A/Ann Arbor/6/60 strain.

Authors:  B R Murphy; H P Holley; E J Berquist; M M Levine; S B Spring; H F Maassab; A P Kendal; R M Chanock
Journal:  Infect Immun       Date:  1979-02       Impact factor: 3.441

7.  Influenza vaccination of elderly persons. Reduction in pneumonia and influenza hospitalizations and deaths.

Authors:  W H Barker; J P Mullooly
Journal:  JAMA       Date:  1980-12-05       Impact factor: 56.272

8.  Influenza vaccination and mortality from bronchopneumonia in the elderly.

Authors:  C H Howells; C K Vesselinova-Jenkins; A D Evans; J James
Journal:  Lancet       Date:  1975-02-15       Impact factor: 79.321

9.  Persistence of influenza A/New Jersey/76 (Hsw1N1) antibody one year after vaccination.

Authors:  G R Noble; H S Kaye; R J O'Brien; A P Kendal; D J Bregman; P F Wright; R W Amler; W R Dowdle
Journal:  Dev Biol Stand       Date:  1977 Jun 1-3

10.  Evaluation of influenza A/Hong Kong/123/77 (H1N1) ts-1A2 and cold-adapted recombinant viruses in seronegative adult volunteers.

Authors:  B R Murphy; M B Rennels; R G Douglas; R F Betts; R B Couch; T R Cate; R M Chanock; A P Kendal; H F Maassab; S Suwanagool; S B Sotman; L A Cisneros; W C Anthony; D R Nalin; M M Levine
Journal:  Infect Immun       Date:  1980-08       Impact factor: 3.441

View more
  20 in total

1.  In elderly persons live attenuated influenza A virus vaccines do not offer an advantage over inactivated virus vaccine in inducing serum or secretory antibodies or local immunologic memory.

Authors:  D C Powers; L F Fries; B R Murphy; B Thumar; M L Clements
Journal:  J Clin Microbiol       Date:  1991-03       Impact factor: 5.948

Review 2.  Influenza vaccines. A reappraisal of their use.

Authors:  A M Palache
Journal:  Drugs       Date:  1997-12       Impact factor: 9.546

Review 3.  Is there a role for a mucosal influenza vaccine in the elderly?

Authors:  E M Corrigan; R L Clancy
Journal:  Drugs Aging       Date:  1999-09       Impact factor: 3.923

4.  Increasing doses of purified influenza virus hemagglutinin and subvirion vaccines enhance antibody responses in the elderly.

Authors:  W A Keitel; T R Cate; R L Atmar; C S Turner; D Nino; C M Dukes; H R Six; R B Couch
Journal:  Clin Diagn Lab Immunol       Date:  1996-09

Review 5.  Mucosal vaccines for the prevention of influenza.

Authors:  R L Clancy
Journal:  Drugs       Date:  1995-10       Impact factor: 9.546

6.  Immunoglobulin A (IgA) responses and IgE-associated inflammation along the respiratory tract after mucosal but not systemic immunization.

Authors:  L M Hodge; M Marinaro; H P Jones; J R McGhee; H Kiyono; J W Simecka
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

Review 7.  Intranasal cold-adapted influenza virus vaccine combined with inactivated influenza virus vaccines: an extra boost for the elderly?

Authors:  Paul V Targonski; Gregory A Poland
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

8.  Influenza vaccination in older patients. Immunogenicity, epidemiology and available agents.

Authors:  H Glathe; W Lange
Journal:  Drugs Aging       Date:  1995-05       Impact factor: 3.923

9.  Impact of post-thymic cellular longevity on the development of age-associated CD4+ T cell defects.

Authors:  Stephen C Jones; Karen Clise-Dwyer; Gail Huston; John Dibble; Sheri Eaton; Laura Haynes; Susan L Swain
Journal:  J Immunol       Date:  2008-04-01       Impact factor: 5.422

10.  Impaired immune responses in the lungs of aged mice following influenza infection.

Authors:  Franklin R Toapanta; Ted M Ross
Journal:  Respir Res       Date:  2009-11-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.